Kathryn Ardizzone, KEI Comment to NIST Regarding Proposal to Deny Members of the Public Standing to Appeal Government Licenses

Posted on by Kathryn Ardizzone

PDF version here: KA-KEI-NIST-Standing-26March2021 More on the NIST proposed changes to the Bayh-Dole Regulations: https://www.keionline.org/35432 Kathryn Ardizzone Counsel, Knowledge Ecology International National Institute of Standards and Technologies Rights to Federally Funded Inventions and Licensing of Government Owned Inventions Docket No.:… Continue Reading →

Luis Gil Abinader NIST comments on the definition of Subject Invention, 26 March 2021

Posted on by Luis Gil Abinader

PDF version here:LGA-NIST-Subject-Invention-definition-26March2021 More on the NIST proposed changes to the Bayh-Dole Regulations. https://www.keionline.org/35432 Comments of Luis Gil Abinader of Knowledge Ecology International on the redefinition of “Subject Invention” to Narrow the Inventions to Which Government Rights Attach (Modify 37… Continue Reading →

On Joe Allen’s claims that former Senators can provide authoritative statements on legislative intent decades after leaving office, especially when they worked as lobbyists

Posted on by Kathryn Ardizzone

A recent blog published in IPWatchdog expresses outrage at accurate observations made by James Love, director of Knowledge Ecology International (KEI), that former Senators Birch Bayh and Bob Dole acquired financial ties to the pharmaceutical industry between the enactment of… Continue Reading →

KEI Comments on NIH Proposed Exclusive License to Iovance for Cancer Cell Therapy

Posted on by Claire Cassedy

On Friday March 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Engineered Tumor Infiltrating Lymphocytes for Cancer Therapy” (86 FR 11548). The technology is… Continue Reading →

Canada based Biolyse Pharma Seeks to Manufacture COVID-19 Vaccines for Low-Income Countries, may test Canada’s compulsory licensing for export law

Posted on by Arianna Schouten

On March 11th 2021, Biolyse Pharma (“Biolyse”) issued a statement publicly indicating their capacity to manufacture a COVID-19 vaccine and their intent to apply for a compulsory license in Canada. Biolyse is a Canadian manufacturer of cancer drugs based out… Continue Reading →

KEI Comments on NIH Exclusive Licenses to Kyverna on CAR T therapy

Posted on by Claire Cassedy

(Update: The NIH provided responses to our comments on April 5, 2021 – 86 FR 10092 Response and 86 FR 10081 Response) On Friday March 5, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institute of Health (NIH)… Continue Reading →

Hungarian compulsory license for remdesivir raises a stir with BIO, PhRMA and the US Chamber of Commerce

Posted on by Thiru

Whilst TRIPS Council deliberations in 2020 witnessed some lively deliberations on the nature of legislative amendments to Hungary’ special legal order (State of Danger) to enable the provision of a “compulsory licence regime for public health purposes”, Hungary’s recent decision… Continue Reading →